A too classic history (whether biotech or medtech) of a program which got lost in the strategic reconsiderations and reorganisations of the acquirer(s); at least, despite significant delays, patients should benefit from it eventually. Let's hope that with the latest ESG pressure coming from all sides this might change priorities and large companies shall feel less accountable first to the bottom line (much needed though, as less profit means less investments) so as to support to the finish line less cash generative but yet live saving programs. Some clever economic incentives for all stakeholders would only help for sure.
then it will be on the tab of taxpayers money and/or philantropy (often involving tax rebates to make it happen) to avoid another bankruptcy; my concern is that creativity is not what is missing, we probably have thought about many incentives, so it is hard for me to anticipate when interests of all parties will be aligned to make it work for industry (and therefore then VCs) to come back in the picture
A too classic history (whether biotech or medtech) of a program which got lost in the strategic reconsiderations and reorganisations of the acquirer(s); at least, despite significant delays, patients should benefit from it eventually. Let's hope that with the latest ESG pressure coming from all sides this might change priorities and large companies shall feel less accountable first to the bottom line (much needed though, as less profit means less investments) so as to support to the finish line less cash generative but yet live saving programs. Some clever economic incentives for all stakeholders would only help for sure.
Thanks Bruno. Yes - economic incentives - but this, once again, does not look like the year for progress . . .
then it will be on the tab of taxpayers money and/or philantropy (often involving tax rebates to make it happen) to avoid another bankruptcy; my concern is that creativity is not what is missing, we probably have thought about many incentives, so it is hard for me to anticipate when interests of all parties will be aligned to make it work for industry (and therefore then VCs) to come back in the picture
couldn't agree more . . .